- Search results for Bharat Biotech
| Image | Title | |
|---|---|---|
 | Without consulting a doctor, paracetamol not recommended for teenagers post-vaccination. Here's whyAches, fatigue, headache, soreness at the injection site and low-grade fever are common after the first two days of vaccination and they tend to subside on their own sans any medication | |
 | One in every four children vaccinated in K'taka, plan on to vaccinate all 15 to 18 year olds in 15 daysAs many as 3.50 lakh adolescents received their first shot in the state on the first day itself and after 28 days, the state will be administering the second dose of Covaxin
| |
 | Covaxin gets nod from India's Central Drug Authority to give to children aged 2 to 18 years. But it's not for everyoneWhen DGCI will grant final approval, Covaxin will be the second vaccine for the use of kids after Zydus Cadila's three-dose DNA jab is used for children above 12 years | |
 | Covaxin will soon be manufactured in Bengaluru too, Bharat Biotech seeks expansionIn April, Bharat Biotech had announced the expansion of its manufacturing capacity across multiple facilities in Hyderabad and Bengaluru to produce 700 million doses of Covaxin annually | |
 | Two-year-old gets vaccine jab in UP as part of Bharat Biotech's ongoing Covaxin trialsIn May, the Drugs Controller General of India (DCGI) had granted permission to Bharat Biotech to commence phase 2-3 trials of Covaxin on children as young as two | |
| Bharat Biotech to release results of Phase 3 trials of Covaxin in JulyThis comes amid a raging debate on a recent pre-print study which said that while both Covaxin and Covishield showed a good immune response, Covishield produced more antibodies than Covaxin | |
| Covaxin batch initiated in March will only be ready for supply in June: Bharat BiotechThe manufacturing, testing, release and distribution of vaccines are complex and multi-factorial processes with hundreds of steps, requiring a diverse pool of human resources, the firm said | |
 | Bharat Biotech cuts Covaxin price for states to Rs 400 after widespread criticismThis follows a widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose | |
 | Government asks Serum Institute, Bharat Biotech to lower the price of COVID-19 vaccines: Official sourcesThe Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals | |
| Avoid Covaxin in case of allergies, fever: Bharat BiotechThe Hyderabad-based vaccine-maker, in a fact sheet for recipients and caregivers, said that even pregnant and nursing women should not take the vaccine | |
| Bharat Biotech seeks DCGI's approval to conduct trials of nasal COVID-19 vaccineCOVID-19 vaccines of Serum Institute of India's 'Covishield' and Bharat Biotech's 'Covaxin' were granted permission for restricted use in an emergency situation by the DCGI on January 3 | |
 | SII, Bharat Biotech's COVID-19 vaccines approved for restricted use in emergency situationsThe SEC of Standard Drug Organisation met on 1st and 2nd Jan and made recommendations in respect of proposal of restructed emergency approval of COVID-19 vaccine of SII, according to DCGI | |
 | Bharat Biotech Chairman and MD discuss Covaxin status with Vice-PresidentDuring the interaction, the Vice-President lauded the collaboration between the ICMR and Bharat Biotech and stressed the importance of public-private partnership | |
| Bharat Biotech recruits 13,000 volunteers for Covaxin Phase III trialsThe Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India | |
 | CSIR's project to develop human antibodies for COVID-19 will be led by Bharat BiotechAlthough efforts are underway for the development of drugs and vaccines for controlling the COVID-19 pandemic, the processes are slow and expensive and have uncertainties |
Search results 1 - 15 of 15